Study guide

9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

Key Takeaways Explain This Topic AI

The bleeding time is prolonged in thrombocytopenia, platelet function disorders, von Willebrand disease, and aspirin use, but it is normal in hemophilia.

In the tourniquet test, the cuff is held midway between systolic and diastolic pressure for 5 minutes, and 10 or more petechiae per square inch is positive under the 2011 WHO dengue guidelines.

Glanzmann thrombasthenia shows absent aggregation to all agonists except ristocetin, while Bernard-Soulier syndrome shows absent ristocetin aggregation that normal plasma does not correct.

Hereditary spherocytosis increases osmotic fragility, while thalassemia, sickle cell disease, and other target-cell conditions decrease it.

In the G6PD fluorescent spot test, normal samples fluoresce under UV light because NADPH forms, while deficient samples fail to fluoresce.

Last updated: October 2026

Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

The Hematology blueprint lists coagulation tests as including bleeding time, clotting time, prothrombin time, and red cell fragility, and it reserves 5% for special tests. Several of these older tests are rarely ordered now, but they remain on the board because they teach the physiology behind modern assays and are still used where analyzers are limited. This section covers bleeding and clotting times, clot retraction, the tourniquet test (important in dengue), platelet aggregation and the PFA-100, osmotic fragility, PNH testing, G6PD screening, sickling tests, and the LE cell preparation.

1. Bleeding Time

The bleeding time measures how quickly a standardized skin puncture stops bleeding, which depends on platelet number and function and on vessel wall integrity (primary hemostasis).

Method Technique Approximate Normal Range

Duke Earlobe puncture with a lancet; blot the drop every 15 to 30 seconds without touching the wound About 1 to 3 minutes (up to about 5)

Ivy Blood pressure cuff on the upper arm inflated to 40 mm Hg ; standardized incisions on the volar forearm (template device); blot every 30 seconds About 2 to 7 minutes (template methods up to about 9 to 10 minutes)

Prolonged in: Thrombocytopenia, qualitative platelet disorders (Glanzmann thrombasthenia, Bernard-Soulier syndrome), von Willebrand disease, aspirin and other antiplatelet drugs, uremia, and vascular disorders.

Normal in: Coagulation factor deficiencies such as hemophilia A and B (the platelet plug forms normally).

Limitations: Poor reproducibility and no ability to predict surgical bleeding. Aspirin should be stopped about 7 to 10 days before testing when the test is used to assess an inherited disorder.

2. Whole Blood Clotting Time and Clot Retraction

Lee-White (tube) clotting time: Venous blood is placed in three glass tubes at 37 °C; the tubes are tilted at intervals until the blood no longer flows. The normal range is commonly quoted as about 5 to 15 minutes . It is prolonged in severe factor deficiencies, heparin therapy, and afibrinogenemia, but it is insensitive to mild deficiencies and has been replaced by the aPTT.

Capillary tube (slide) clotting time: A capillary tube filled from a fingerstick is broken at intervals until a fibrin thread appears; the normal range is about 2 to 4 minutes (some texts give up to 5 to 6 minutes). It is a crude bedside test.

Clot retraction: Blood clotted in a tube at 37 °C normally retracts and expresses serum. Retraction is visible within about 1 hour and largely complete within 24 hours, when the clot has shrunk to roughly half of the original blood volume. Retraction depends on platelet number and on functional glycoprotein IIb/IIIa and the platelet contractile proteins. It is poor in thrombocytopenia and Glanzmann thrombasthenia . Severe anemia increases apparent retraction, and polycythemia decreases it.

3. Tourniquet Test (Rumpel-Leede Capillary Fragility Test)

Procedure: Inflate a blood pressure cuff on the upper arm to a pressure midway between systolic and diastolic pressure for 5 minutes . Release the cuff, wait about 1 to 2 minutes, and count the petechiae in a 2.5 cm × 2.5 cm (1-inch) square on the forearm or antecubital area.

Interpretation: The WHO dengue guidelines for South-East Asia (2011) treat 10 or more petechiae per square inch as positive; older WHO criteria used 20 or more.

Significance: A positive test reflects capillary fragility and thrombocytopenia. In the Philippines, where dengue is endemic, it is part of the bedside assessment of probable dengue and is interpreted together with the platelet count, hematocrit (hemoconcentration), and NS1 antigen or serology. It is also positive in other thrombocytopenias and vasculitides.

  • 4. Platelet Aggregation Studies and the PFA-100
  • Light Transmission Aggregometry

Platelet-rich plasma is stirred at 37 °C in an aggregometer. When an agonist is added and platelets clump, the plasma clears and light transmission increases . Standard agonists are ADP, epinephrine, collagen, arachidonic acid, and ristocetin.

  • Condition ADP Epinephrine Collagen Arachidonic Acid Ristocetin
  • Glanzmann thrombasthenia (GP IIb/IIIa defect) Absent Absent Absent Absent Normal

Bernard-Soulier syndrome (GP Ib/IX/V defect) Normal Normal Normal Normal Absent, not corrected by normal plasma

von Willebrand disease Normal Normal Normal Normal Decreased or absent, corrected by normal plasma (supplies von Willebrand factor)

  • Aspirin effect Primary wave only (no secondary wave) Primary wave only Decreased Absent Normal
  • Storage pool disease Primary wave only Primary wave only Decreased Variable Normal

Specimens are drawn in 3.2% citrate with minimal trauma, kept at room temperature (cold activates platelets), and tested within about 4 hours.

Ristocetin causes von Willebrand factor to bind platelet GP Ib, so it tests the vWF-GP Ib interaction. Bernard-Soulier syndrome also features giant platelets and thrombocytopenia.

PFA-100 (Platelet Function Analyzer)

Citrated whole blood is drawn under high shear through an aperture in a membrane coated with collagen/epinephrine or collagen/ADP . The closure time is the time taken for a platelet plug to occlude the aperture.

Prolonged with both cartridges: von Willebrand disease, Glanzmann thrombasthenia, Bernard-Soulier syndrome, thrombocytopenia, and anemia (low hematocrit).

Aspirin typically prolongs the collagen/epinephrine closure time while the collagen/ADP closure time stays normal.

  • 5. Red Cell Fragility and Hemolysis Tests
  • Osmotic Fragility Test

Red cells are added to a series of hypotonic sodium chloride solutions (commonly from 0.85% down to about 0.10%). Water enters the cells, and they lyse when their volume exceeds their capacity to swell. The percentage of hemolysis in each tube is read photometrically.

Normal: Hemolysis begins at about 0.45% to 0.50% NaCl and is complete at about 0.30% to 0.35%.

Increased fragility (lysis at higher salt concentrations): Hereditary spherocytosis and other spherocytic states (warm autoimmune hemolytic anemia), because spherocytes have a low surface-area-to-volume ratio. Incubating the blood at 37 °C for 24 hours before testing makes mild spherocytosis easier to detect.

Decreased fragility (resistance to lysis): Thalassemia, sickle cell disease, iron deficiency, and other conditions with target cells or flattened cells that have extra membrane.

The flow cytometric eosin-5'-maleimide (EMA) binding test is now a preferred screening test for hereditary spherocytosis.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH cells lack GPI-anchored complement-regulatory proteins ( CD55 and CD59 ) and are lysed by complement.

Historical tests: The sucrose hemolysis test (screen; low ionic strength promotes complement binding) and Ham's acidified serum test (confirmation; acidified serum activates the alternative complement pathway).

Current standard: Flow cytometry showing loss of CD55 and CD59 on red cells and loss of GPI-anchored proteins on granulocytes and monocytes, often with FLAER (fluorescent aerolysin), which binds the GPI anchor itself.

G6PD Deficiency Screening

G6PD deficiency is the most common red cell enzyme defect worldwide and is included in the Philippine newborn screening panel. Oxidant stress (fava beans, sulfonamides, primaquine, infections) precipitates hemoglobin as Heinz bodies and causes hemolysis, and bite cells appear on the smear.

Fluorescent spot test (Beutler): Blood is mixed with glucose-6-phosphate and NADP+. Normal G6PD reduces NADP+ to NADPH, which fluoresces under long-wave UV light . Deficient samples do not fluoresce .

During or just after a hemolytic episode, the oldest and most deficient cells have already been destroyed, and the reticulocytes have higher G6PD activity, so a falsely normal result is possible. Repeat the test after recovery.

Heinz bodies are shown with a supravital stain such as crystal violet or brilliant cresyl blue, not with Wright stain.

Sickling and Solubility Tests

Sodium metabisulfite slide test: A reducing agent deoxygenates hemoglobin under a sealed coverslip, and red cells containing HbS form sickles.

Solubility (dithionite) test: Deoxygenated HbS is insoluble in a high-phosphate buffer and makes the solution turbid , while other hemoglobins stay in solution and the lines behind the tube remain visible. False negatives occur in infants under about 6 months (high HbF) and with severe anemia. Both tests detect HbS but cannot separate sickle trait from sickle cell disease; hemoglobin electrophoresis or HPLC is required.

6. The LE Cell Preparation (Historical)

In the LE cell test , blood from a patient with systemic lupus erythematosus is traumatized and incubated so that antinuclear antibodies coat exposed nuclei. A neutrophil that has engulfed the homogeneous, glassy, purple nuclear material is an LE cell , and the nucleus is pushed to the side.

A tart cell is a monocyte that has ingested a nucleus that still shows chromatin structure. It is not an LE cell.

The LE cell test was insensitive and has been replaced by antinuclear antibody (ANA) testing and anti-dsDNA antibodies (see the autoimmune serology section).